Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03281811 · ClinicalTrials.gov registry record · Early Phase 1
Photodynamic Therapy in Treating Patients With Refractory Mycosis Fungoides
A Early Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 11
- Enrollment target
NCT03281811: Completed Early Phase 1 study, sponsored by Mayo Clinic.
NCT03281811 is a Early Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03281811, a Early Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This pilot phase II trial studies how well photodynamic therapy works in treating patients with mycosis fungoides that does not respond to treatment. Photodynamic therapy uses a drug, such as aminolevulinic acid hydrochloride, that becomes active when it is exposed to light. The activated drug may kill cancer cells.
Interventions
- OTHER Quality-of-Life Assessment
- RADIATION Radiation Therapy
- DRUG Photodynamic Therapy
- DRUG Aminolevulinic Acid Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2017-11-13 |
| Est. Completion | 2020-08-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03281811
The ClinicalTrials.gov registry entry for NCT03281811 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.
NCT03281811 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03281811 about?
NCT03281811 is a clinical study titled "Photodynamic Therapy in Treating Patients With Refractory Mycosis Fungoides". This pilot phase II trial studies how well photodynamic therapy works in treating patients with mycosis fungoides that does not respond to treatment. Photodynamic therapy uses a drug, such as aminolevulinic acid hydrochloride, that becomes active when it is exposed to light. The activated drug may k...
What is the current status of trial NCT03281811?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 11 participants. The study started on 2017-11-13. Estimated completion is 2020-08-12.
What interventions are being tested in trial NCT03281811?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Radiation Therapy (RADIATION), Photodynamic Therapy (DRUG), Aminolevulinic Acid Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT03281811?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.